Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.
Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 2 OBA trial of BIO101, targeting muscle wasting associated with obesity. This new program underscores Biophytis’s ambition to broaden the potential of its…
Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis announced that both Part I (European Medicines Agency scientific review) and Part II (Belgian national ethical assessment) of its Clinical Trial Application (CTA) for a Phase 3 study in sarcopenia have been successfully reviewed and…
Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Biophytis announces the establishment of a non-dilutive bond financing line for a maximum amount of €1 million with Hexagon Capital Fund, with an initial subscription of €100,000. Fullscreen Mode
Biophytis Joins Silver Innov’, an Incubator Dedicated to the Silver Economy Biophytis is relocating to Silver Innov, an incubator and business center specialized in innovation, healthcare, and aging. This move represents a key milestone in Biophytis’ strategic roadmap, reinforcing its presence within an ecosystem dedicated to the silver economy, healthy…
Biophytis Wins Major Legal Victory Before the French Court of Cassation Biophytis announces a major legal victory. On July 9, 2025, the French Court of Cassation, the country’s highest judicial authority, issued a landmark ruling partially overturning the decision of the Paris Court of Appeal and ruling in favor of…
Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to…
Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced…
Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025 Biophytis announces its participation in the 7th edition of the World Aging & Rejuvenation Conference (ARC 2025), to be held in Vienna, Austria, from July 9 to 10, 2025. As part of this internationally renowned…
Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized…
Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025 Biophytis is proud to announce its successful participation at the BIO International Convention 2025, the world’s largest and most comprehensive biotechnology event. Hosted at the Boston Convention & Exhibition Center from June 16-19, 2025, the convention gathered…
Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode
Biophytis announces the temporary suspension of the trading of its shares Biophytis announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the…
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Our lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.
BIOPHYTIS ON THE STOCK MARKET
Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015.
ISIN FR001400OLP5
Ticker: ALBPS
Type of listing: continuous
Total number of shares at 31/07/2025: 24,624,450
1 ADR = 10 shares
Number of voting rights at 31/07/2025: 24,658,929
Eligible for PEA and PEA-PME equity saving plans
Click here for live stock price